Hexaell Biotech

Based in Shanghai, China and founded in 2015, Hexaell Biotech Co. , Ltd. , dba Hexaell Biotech, operates as a biotechnology company specializing in developing novel cell therapies and regenerative medicines for severe liver diseases. In July 2017, the company established a production line for clinical research and development of human hepatocyte-derived bioartificial liver in Jiading, Shanghai.

In April 2026, Hexaell Biotech raised approximately CNY 100 million in series B++ funding from Fuho Capital, Guangdong Technology Financial Group, Shumyip Capital, Cuiheng Group and Zhongshan Venture Capital. Hexaell Biotech focuses on severe liver diseases and cell therapy. It uses hepatocyte trans-differentiation and expansion technology to build the HepaCure bioartificial liver support system, which is an in vitro liver function support system suitable for patients with liver failure and postoperative rehabilitation of patients with liver resection. The company also uses primary hepatocyte in vitro expansion technology to build proliferating human primary hepatocytes ProliHH, which can be used for hepatocyte transplantation to treat genetic metabolic liver diseases, and drug screening and other R&D services.

The company generates revenue by providing bioartificial liver products and hepatocyte transplant products, as well as developing cell therapy technologies. The company will use the series B++ funding for the clinical development, process optimization, and subsequent pipeline development of its core product, HepaCure bioartificial liver, further solidifying its position in the field of liver disease treatment.